Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 17.9% in December

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totaling 16,697 shares, a decrease of 17.9% from the December 15th total of 20,342 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 3,946 shares, the short-interest ratio is currently 4.2 days. Based on an average trading volume of 3,946 shares, the short-interest ratio is currently 4.2 days. Approximately 0.0% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MOLN. JPMorgan Chase & Co. decreased their price objective on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating on the stock in a report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a research report on Monday, December 22nd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $7.88.

Molecular Partners Stock Performance

MOLN traded down $0.14 during trading on Tuesday, reaching $4.06. 10,496 shares of the company’s stock were exchanged, compared to its average volume of 4,958. The company’s fifty day moving average price is $4.26 and its 200-day moving average price is $3.92. The firm has a market capitalization of $163.92 million, a PE ratio of -2.11 and a beta of 1.07. Molecular Partners has a fifty-two week low of $3.36 and a fifty-two week high of $5.41.

Molecular Partners (NASDAQ:MOLN) last posted its earnings results on Thursday, October 30th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.05. Research analysts forecast that Molecular Partners will post -1.93 earnings per share for the current fiscal year.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.